胶质瘤患者及其家庭照护者的医疗资源利用与生产力损失:可治疗心理症状的影响
基于多中心随机试验数据,分析91例胶质瘤患者和46例照护者从基线至12个月的医疗与社会成本,患者年均总成本为20587.53欧元(标准差30910.53),照护者为5581.49欧元(标准差13102.82);患者抑郁症状与较高医疗利用成本相关,照护者疲劳、认知抱怨与较高总成本相关,提示可治疗心理症状可能影响成本。
要点
- 胶质瘤患者年均总成本为20587.53欧元(标准差30910.53),照护者为5581.49欧元(标准差13102.82)。
- 患者抑郁症状较多与较高医疗利用成本相关,活动性/进展性疾病与较高药物成本相关。
- 照护者疲劳、认知抱怨及患者较低肿瘤级别与较高总成本相关(均P<0.05)。
核心结论
- 胶质瘤患者和照护者存在巨大的医疗与社会成本;成本与可治疗心理症状之间的关联提示,适当的支持可能降低费用。
研究设计与样本
- 基于多中心随机试验(NTR3223)数据,分析互联网心理治疗对抑郁症状效果研究中的成本数据,分别计算患者和照护者自我报告的医疗利用、用药及生产力损失成本,采用广义线性回归模型预测成本。
主要发现
- 共纳入91例胶质瘤患者和46例照护者从基线至12个月多次评估的数据;患者年均总成本为20587.53欧元(标准差30910.53),照护者为5581.49欧元(标准差13102.82)。
- 患者中,较高医疗利用成本与更多抑郁症状相关;较高药物成本与活动性/进展性疾病相关。
- 照护者中,较高总成本与照护者疲劳增加、认知抱怨及患者较低肿瘤级别相关;较高医疗利用成本与更多认知抱怨和较低肿瘤级别相关;较高生产力损失成本与疲劳增加相关(均P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gliomas are associated with significant healthcare burden, yet reports of costs are scarce. While many costs are unavoidable there may be treatable symptoms contributing to higher costs. We describe healthcare and societal costs in glioma patients at high risk for depression and their family caregivers, and explore relationships between costs and treatable symptoms. METHODS: Data from a multicenter randomized trial on effects of internet-based therapy for depressive symptoms were used (NTR3223). Costs of self-reported healthcare utilization, medication use, and productivity loss were calculated for patients and caregivers separately. We used generalized linear regression models to predict costs with depressive symptoms, fatigue, cognitive complaints, tumor grade (low-/high-grade), disease status (stable or active/progression), and intervention (use/non-use) as predictors. RESULTS: Multiple assessments from baseline through 12 months from 91 glioma patients and 46 caregivers were used. Mean overall costs per year were M = €20,587.53 (sd = €30,910.53) for patients and M = €5,581.49 (sd = €13,102.82) for caregivers. In patients, higher healthcare utilization costs were associated with more depressive symptoms; higher medication costs were associated with active/progressive disease. In caregivers, higher overall costs were linked with increased caregiver fatigue, cognitive complaints, and lower patient tumor grade. Higher healthcare utilization costs were related to more cognitive complaints and lower tumor grade. More productivity loss costs were associated with increased fatigue (all P < 0.05). CONCLUSIONS: There are substantial healthcare and societal costs for glioma patients and caregivers. Associations between costs and treatable psychological symptoms indicate that possibly, adequate support could decrease costs. TRIAL REGISTRATION: Netherlands Trial Register NTR3223.
引用
- Boele FW, Meads D, Jansen F, et al. Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. J Neurooncol. 2020. PMID: 32172441. doi:10.1007/s11060-020-03454-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。